FMC, DE0005785802

Dialysegerät 6008 Care System by Fresenius Medical Care AG - focus on efficiency

Published on 07/18/2026 at 09:59 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS

Dialysegerät 6008 Care System delivers high-volume hemodiafiltration with automated workflows for busy dialysis clinics. This product is driving the price of Fresenius Medical Care AG stock (ISIN DE0005785802).

Trading-Monitore mit MDAX-Index und Healthcare-Sektorindex, Hände auf Tastatur im Vordergrund
Eine Finanz-Editorial-Aufnahme mit Trading-Monitoren, MDAX-Kursdaten und einem Healthcare-Sektorindex – passend zum Börsenkontext der Fresenius Medical Care AG (ISIN DE0005785802) als MDAX-notiertes Medizintechnikunternehmen, Illustration mit AI erstellt.

Dialysegerät 6008 Care System stands in the treatment room like a white monolith, its touchscreen glowing softly while nurses adjust lines and listen to the quiet hum of the pumps. The plastic tubing feels cool and slightly stiff as Dr. Michael Hofmann checks the connections before starting the next high-volume hemodiafiltration session. Fresenius Medical Care AG positions the 6008 Care System as a hemodialysis platform that brings automation and advanced therapies into everyday dialysis practice.

What the 6008 Care System does

The 6008 Care System is a hemodialysis and hemodiafiltration device designed for chronic kidney disease patients treated in professional dialysis centers. It supports both standard hemodialysis and high-volume online hemodiafiltration, intended to increase convective clearance of middle molecules compared with conventional dialysis. According to Fresenius Medical Care, the system automates routine tasks such as dialyzer priming and rinse-back to reduce manual steps for nursing staff.

The device is part of Fresenius Medical Care’s 6008 series therapies, combining the machine with compatible disposables and treatment concepts under the company’s haemodialysis portfolio. On the product page, Fresenius highlights integrated blood volume monitoring and pressure control features designed to help clinicians manage ultrafiltration and patient hemodynamics during treatment. The 6008 Care System is primarily targeted at in-center dialysis operators rather than home use.

Dig deeper & contextualize

Fresenius Medical Care AG in focus

Dialysis devices like the 6008 Care System sit at the core of Fresenius Medical Care AG’s treatment business and revenue mix.

Design and workflow in the clinic

From the nurse’s perspective, the 6008 Care System is built around a central touchscreen and a structured user interface that guides through treatment steps. Fresenius emphasizes that key actions, such as starting therapy or adjusting parameters, can be completed with relatively few taps, aiming to keep workflows predictable during busy shifts. In practice, staff move quickly around the machine, feeling the slight vibration of the pump housing when blood flow rises.

The device uses dedicated bloodlines and dialyzers that are part of Fresenius Medical Care’s consumable range, tying the hardware into the broader therapy ecosystem. Automated processes like dialyzer priming, online fluid preparation and rinse-back are designed to cut down on manual time spent at each station, which can be significant in centers with dozens of patients per day. At the same time, alarms and safety interlocks give acoustic and visual feedback when parameters fall outside the defined range.

Technical features and therapy modes

According to the manufacturer, the 6008 Care System can deliver high-volume online hemodiafiltration by generating substitution fluid from ultrapure dialysis fluid and infusing it either pre- or post-dialyzer. Fresenius describes treatment volumes above 20 liters of substitution fluid per session as a typical target for high-volume therapy, depending on patient prescription and session length. The machine’s built-in software controls fluid balancing, pressure monitoring and blood flow rates to maintain accuracy across the treatment.

The system integrates sensors that monitor venous and arterial pressures, dialysate conductivity and temperature. Fresenius Medical Care also mentions blood volume tracking features that help clinicians assess intradialytic volume changes. These functions can support decisions on ultrafiltration rates, aiming to reduce intradialytic hypotension in susceptible patients, although outcomes depend on clinical practice. Therapy prescriptions, patient data and machine parameters can be connected into the clinic’s data infrastructure using Fresenius’s documentation solutions where installed.

On the official product page, the company clarifies that the 6008 Care System is intended for use by healthcare professionals in dialysis centers and hospitals. It is not a home dialysis device; instead, it operates in multi-bed facilities, often in combination with water treatment systems and an array of identical machines. In this setting, therapy standardization and reproducible machine behavior are priorities.

Regulatory and market position

Fresenius Medical Care markets the 6008 Care System as part of its haemodialysis portfolio in Europe and other regions, subject to local regulatory approvals such as CE marking in the EU. In company materials, the system is presented alongside predecessor platforms and related disposables, indicating that it replaces or complements older 5008 series devices in many centers. The product is typically sold to dialysis providers under capital equipment contracts combined with consumables supply.

In press and analyst coverage, Fresenius’s hemodialysis machines, including the 5008 and 6008 families, are repeatedly named as core assets within the company’s Care Delivery segment. The CEO of Fresenius Medical Care, Carla Kriwet, has underlined in recent interviews that therapy quality and efficiency in dialysis centers remain central to the business strategy. Equipment like the 6008 Care System helps underpin recurring revenue streams from disposables and services linked to long-term patient care.

Context, competition and Fresenius Medical Care stock

The 6008 Care System competes in a technical market where other manufacturers, such as Baxter and Nikkiso, also offer hemodialysis and hemodiafiltration platforms for chronic therapy. Differences in interfaces, fluid systems and monitoring options matter to clinical teams, but procurement decisions often revolve around lifecycle costs, reliability and integration with consumables and service contracts. Fresenius Medical Care’s long-standing presence in global dialysis markets gives the 6008 Care System a strong installed-base advantage in many regions.

For Fresenius Medical Care AG, dialysis devices and associated products remain a major revenue pillar highlighted in investor presentations. The Fresenius Medical Care AG stock is listed on Xetra in euro; analysts frequently point to the dialysis equipment and services portfolio, including systems like the 6008 Care System, as an important driver of recurring income.

Key facts on the Dialysegerät 6008 Care System

  • Product: Dialysegerät 6008 Care System
  • Manufacturer: Fresenius Medical Care AG
  • Category: B2B/Pro line
  • Market launch: Not publicly specified; introduced as part of the 6008 therapy system family in recent years
  • MSRP / Price: Not publicly disclosed; sold via capital equipment contracts
  • Availability: Available to professional dialysis providers in multiple regions, subject to local regulatory approvals
  • Target group: Dialysis centers and hospitals treating chronic kidney disease patients
  • Highlight / USP: Supports high-volume online hemodiafiltration with extensive automation of dialysis workflows

Further media on Dialysegerät 6008 Care System

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | DE0005785802 | FMC | boerse | 69793762 | bgmi